Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertugliflozin/sitagliptin - Merck/Pfizer

Next Previous
Search
Drug Profile

Ertugliflozin/sitagliptin - Merck/Pfizer

Alternative Names: MK 8835/MK 0431; MK 8835A; STEGLUJAN

Latest Information Update: 17 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 16 Feb 2022 Discontinued - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment) in New Zealand, Canada, Ukraine, Mexico, Thailand, Russia, Malaysia, Israel, Philippines, Philippines, Argentina, Colombia (PO)
  • 01 Mar 2018 Registered for Type-2 diabetes mellitus in European Union (PO)
  • 25 Jan 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of ertugliflozin/sitagliptin for Type-2 diabetes mellitus in European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top